A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.
Eich, Andreas; Urban, Veronika; Jutel, Marek; Vlcek, Jiri; Shim, Jae Jeong; Trofimov, Vasiliy I; Liam, Chong-Kin; Kuo, Ping-Hung; Hou, Yanyan; Xiao, Jun; Branigan, Patrick; O'Brien, Christopher D.
; 14(5): 476-483, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28753067
Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations.
A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease.
[Interleukin-17 expression and clinical significance in the lung tissue of patients with stable chronic obstructive pulmonary disease].
Microbiota Promotes Chronic Pulmonary Inflammation by Enhancing IL-17A and Autoantibodies.
PREVALENCE OF COMORBIDITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Interleukin-13: prospects for new treatments.
Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest.
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.
Effects of Low-Dose and Long-Term Treatment with Erythromycin on Interleukin-17 and Interleukin-23 in Peripheral Blood and Induced Sputum in Patients with Stable Chronic Obstructive Pulmonary Disease.